India just got its first-ever dengue vaccine — and it's a big deal.
Qdenga, made by Japan's Takeda, just cleared India's drug regulator (CDSCO) for anyone aged 4 to 60.
Two shots. Three months apart. Protection against all four dengue strains.
But you'll have to wait — it only hits Indian shelves in early 2027.
Here's why this matters more than it sounds.
India logged 1,21,824 dengue cases last year.
And doctors say that number is a lie — a small one.
"It doesn't include patients who only got OPD treatment," says Dr Sunil Havannavar, Senior Consultant at Manipal Hospital, Bengaluru.
Translation: the real number is way higher.
He's already seeing more dengue patients this monsoon than last year's.
His theory?
It's a live-attenuated vaccine — a weakened virus, not a dead one.
Built on a clever "backbone" trick, says Dr Aishwarya R, Aster RV Hospital.
It uses a weakened Dengue Serotype 2 as its base, then adds genetic bits from the other three strains.
One shot. Four-strain coverage.
It's not just an India story either.
Over 24 million doses have already gone into arms across 42 countries — including the EU, UK and Indonesia.
WHO has already prequalified it.
India is simply catching up to a vaccine the world has been quietly rolling out.
This is not a magic shield.
Repeat that last one.
Nets, repellents, no stagnant water — none of that goes away.
India sits among the 5 most dengue-endemic countries on Earth, per WHO.
A homegrown-approved vaccine — even one still 18 months from shelves — is the first real crack in that statistic.
Not a cure.
But finally, a start.
That's all for now!
